Kistler Tiffany Companies, LLC Biomarin Pharmaceutical Inc Transaction History

Kistler Tiffany Companies, LLC

$615 Million
Q2 2023

A detailed history of Kistler Tiffany Companies, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Kistler Tiffany Companies, LLC holds 640 shares of BMRN stock, worth $42,643. This represents 0.01% of its overall portfolio holdings.

Number of Shares

640

Previous 640 -0.0%

Holding current value

$42,643

Previous $62,000 11.29%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 27, 2023	SELL	$80.93 - $108.63 $59,888 - $80,386	-740 Reduced 53.62%	640 $66,000
Q2 2022 Aug 08, 2022	BUY	$71.48 - $86.85 $4,646 - $5,645	65 Added 4.94%	1,380 $114,000
Q1 2022 May 11, 2022	BUY	$74.28 - $92.69 $1,485 - $1,853	20 Added 1.54%	1,315 $101,000
Q4 2021 Jan 25, 2022	BUY	$71.72 - $91.47 $2,151 - $2,744	30 Added 2.37%	1,295 $114,000
Q3 2021 Nov 10, 2021	BUY	$74.77 - $85.47 $13,832 - $15,811	185 Added 17.13%	1,265 $98,000
Q2 2021 Aug 04, 2021	BUY	$75.51 - $84.79 $10,722 - $12,040	142 Added 15.14%	1,080 $90,000
Q1 2021 May 07, 2021	BUY	$74.73 - $90.69 $9,714 - $11,789	130 Added 16.09%	938 $71,000
Q4 2020 Feb 03, 2021	SELL	$72.61 - $90.2 $23,235 - $28,864	-320 Reduced 28.37%	808 $71,000
Q3 2020 Nov 03, 2020	SELL	$71.87 - $131.03 $36,653 - $66,825	-510 Reduced 31.14%	1,128 $86,000
Q2 2020 Jul 20, 2020	SELL	$79.55 - $124.22 $70,163 - $109,562	-882 Reduced 35.0%	1,638 $202,000
Q3 2019 Oct 18, 2019	BUY	$67.4 - $85.11 $36,396 - $45,959	540 Added 27.27%	2,520 $170,000
Q2 2019 Jul 22, 2019	BUY	$80.35 - $93.9 $137,237 - $160,381	1,708 Added 627.94%	1,980 $170,000
Q1 2019 Apr 16, 2019	BUY	$84.2 - $98.62 $22,902 - $26,824	272 New	272 $24,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kistler Tiffany Companies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kistler Tiffany Companies, LLC with notifications on news.

Account

Kistler Tiffany Companies, LLC Biomarin Pharmaceutical Inc Transaction History